Buchumschlag

Editorial: Rebuilding Rome—Revising Diagnostic Criteria for Irritable Bowel Syndrome

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Mohsin F. Butt, Maura Corsetti
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom
von: Mohsin F. Butt, et al.
Veröffentlicht: (2025)

Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care
von: Vivek C. Goodoory, et al.
Veröffentlicht: (2024)

Novel Symptom Subgroups in Patients With Irritable Bowel Syndrome Are Associated With Healthcare Utilisation in Secondary and Tertiary Care
von: Vivek C. Goodoory, et al.
Veröffentlicht: (2026)

Stability of Classification Systems for Irritable Bowel Syndrome
von: Mais Khasawneh, et al.
Veröffentlicht: (2025)

The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance
von: T. E. Conley, et al.
Veröffentlicht: (2026)

Research Communication: An Observational Cohort Study on Risk of Ovarian Cancer in Women with Irritable Bowel Syndrome
von: Andrea Shin, et al.
Veröffentlicht: (2025)

Editorial: Personalising the Low FODMAP Diet to Achieve Therapeutic Benefit Whilst Reducing Burden and Maintaining Dietary Diversity in Irritable Bowel Syndrome. Authors' Reply
von: E. Coss‐Adame, et al.
Veröffentlicht: (2026)

Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice. Authors' Reply
von: Kee Huat Chuah, et al.
Veröffentlicht: (2025)

Research Communication: Healthcare Utilisation Patterns in Patients With Irritable Bowel Syndrome Across an Integrated Healthcare System
von: Neil S. Zheng, et al.
Veröffentlicht: (2025)

Editorial: New Insights Into the Aetiopathogenesis of Post‐Infective Irritable Bowel Syndrome and Functional Dyspepsia: A Significant Step Forward but What Next? Authors' Reply
von: Mohamed H. Eldesouki, et al.
Veröffentlicht: (2026)

Cohort Study: Long‐Term Risk and Healthcare Burden of Irritable Bowel Syndrome Following Infection Enteritis in 202,244 Patients
von: Mohamed H. Eldesouki, et al.
Veröffentlicht: (2026)

Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha‐2‐Delta Ligand PD‐217,014 in Patients With Irritable Bowel Syndrome
von: Lesley A. Houghton, et al.
Veröffentlicht: (2025)

Letter: Irritable bowel syndrome and antibiotics
von: George F. Longstreth
Veröffentlicht: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
von: Kyle Staller, et al.
Veröffentlicht: (2024)

Editorial: Allostatic Load and Inflammatory Bowel Disease
von: Jeli Mendoza, et al.
Veröffentlicht: (2024)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria
von: Julie Bonn, et al.
Veröffentlicht: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
von: Matthew D. Coates, et al.
Veröffentlicht: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
von: Marco Vincenzo Lenti, et al.
Veröffentlicht: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease?
von: Agnes Hiu Yan Ho, et al.
Veröffentlicht: (2025)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria—Authors' Reply
von: Sheila L. Noon, et al.
Veröffentlicht: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
von: Fai Fai Ho, et al.
Veröffentlicht: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues
von: Stephanie Gold, et al.
Veröffentlicht: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
von: Suprabhat Giri, et al.
Veröffentlicht: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
von: Bharati Kochar, et al.
Veröffentlicht: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
von: Nicholas Clark, et al.
Veröffentlicht: (2025)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
von: Purab Patel, et al.
Veröffentlicht: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
von: Joyce Wing Yan Mak
Veröffentlicht: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
von: Jessica A. Fitzpatrick, et al.
Veröffentlicht: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
von: Cristina Rubín de Célix, et al.
Veröffentlicht: (2025)

Editorial: Shooting in the Dark—The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease
von: Jane Lim, et al.
Veröffentlicht: (2025)

Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study
von: J. Tack, et al.
Veröffentlicht: (2025)

Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
von: Konstantinos Papamichael, et al.
Veröffentlicht: (2024)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
von: Aurelien Amiot, et al.
Veröffentlicht: (2025)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
von: Mathieu Uzzan, et al.
Veröffentlicht: (2025)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
von: A. B. Fons, et al.
Veröffentlicht: (2026)

Editorial: Surveillance Colonoscopy for Detection of Neoplasia in Inflammatory Bowel Disease—Is Dye‐Based Chromoendoscopy Always the Final Answer?
von: Andrea Cassinotti, et al.
Veröffentlicht: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
von: Jessica D. Lee, et al.
Veröffentlicht: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
von: Tamar Schildkraut, et al.
Veröffentlicht: (2024)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
von: Suprabhat Giri, et al.
Veröffentlicht: (2025)